- 期刊
卵巢癌的長期維持治療
Long-Term Maintenance or Consolidation of Epithelial Ovarian Cancer
摘要
卵巢癌患者在診斷時多屬晚期，標準治療是在減積手術後，以paclitaxel和carboplatin或cisplatinum作6個療程的術後輔助性化學治療，有效率雖高，但最後大部份患者仍會復發，復發後治癒的機會渺茫，僅在延長生命。最近有些報告提出建議，對首次化學治療後達完全有效的患者，不妨以單一未使用過的有效藥物，作加強或維持治療，對延長生命及生活品質可能較佳，但仍需更多案例的證明。
並列摘要
Most patients with advanced ovarian cancer achieve a clinical complete remission after cytoreductive surgery and combination chemotherapy, usually with six cycles of paclitaxel together with carboplatin. Unfortunately, the majority of patients experience disease recurrence. Although second-line treatments provide effective palliation and may extend survival, they are not curative. Consequently, if an effective consolidation or maintenance therapy that would prevent recurrences after a clinical complete response, it could have a potentially greater impact in advanced ovarian cancer. Generally, maintenance therapies have focused on prolonged administration of single-agent chemotherapy or extended cycles of induction chemotherapy. Several reports have been shown to extend survival in patients with advanced ovarian cancer.
延伸閱讀
- 李耀泰、陳福民、郭宗正（2014）。檢視早期子宮內膜癌保留卵巢的治療。中華民國婦癌醫學雜誌，(2014年2)，16-20。https://www.airitilibrary.com/Article/Detail?DocID=10195998-201410-201411180027-201411180027-16-20
- 李耀泰、陳福民、郭宗正（2012）。卵巢癌的保守性治療。中華民國婦癌醫學雜誌，(2012年2)，65-74。https://doi.org/10.7010/JGO.201210.0065
- 吳芷儀（2019）。卵巢癌治療新趨勢。彰基藥訊，27(3)，5-8。https://www.airitilibrary.com/Article/Detail?DocID=P20140725001-201909-201910050008-201910050008-5-8
- 健康世界編輯部（2016）。復發性卵巢癌治療有新選擇。健康世界，(470)，61-61。https://www.airitilibrary.com/Article/Detail?DocID=16077059-201602-201603150010-201603150010-61-61
- 王功亮、陳子健、陳祈安（2004）。Treatment of Epithelial Ovarian Cancer。台灣醫學，8(5)，738-743。https://doi.org/10.6320/FJM.2004.8(5).22